146 related articles for article (PubMed ID: 8339560)
1. Pilot trial of cyclosporine 1% ophthalmic ointment in the treatment of keratoconjunctivitis sicca.
Laibovitz RA; Solch S; Andriano K; O'Connell M; Silverman MH
Cornea; 1993 Jul; 12(4):315-23. PubMed ID: 8339560
[TBL] [Abstract][Full Text] [Related]
2. A randomized, double-masked, placebo-controlled, multicenter comparison of loteprednol etabonate ophthalmic suspension, 0.5%, and placebo for treatment of keratoconjunctivitis sicca in patients with delayed tear clearance.
Pflugfelder SC; Maskin SL; Anderson B; Chodosh J; Holland EJ; De Paiva CS; Bartels SP; Micuda T; Proskin HM; Vogel R
Am J Ophthalmol; 2004 Sep; 138(3):444-57. PubMed ID: 15364229
[TBL] [Abstract][Full Text] [Related]
3. Topical 0.1% prednisolone lowers nerve growth factor expression in keratoconjunctivitis sicca patients.
Lee HK; Ryu IH; Seo KY; Hong S; Kim HC; Kim EK
Ophthalmology; 2006 Feb; 113(2):198-205. PubMed ID: 16360211
[TBL] [Abstract][Full Text] [Related]
4. Open-label crossover study of vitamin A ointment as a treatment for keratoconjunctivitis sicca.
Gilbard JP; Huang AJ; Belldegrun R; Lee JS; Rossi SR; Gray KL
Ophthalmology; 1989 Feb; 96(2):244-6. PubMed ID: 2704543
[TBL] [Abstract][Full Text] [Related]
5. A double-masked comparison of 0.1% tacrolimus ointment and 2% cyclosporine eye drops in the treatment of vernal keratoconjunctivitis in children.
Labcharoenwongs P; Jirapongsananuruk O; Visitsunthorn N; Kosrirukvongs P; Saengin P; Vichyanond P
Asian Pac J Allergy Immunol; 2012 Sep; 30(3):177-84. PubMed ID: 23156846
[TBL] [Abstract][Full Text] [Related]
6. Topical fibronectin in the treatment of keratoconjunctivitis sicca. Chiron Keratoconjunctivitis Sicca Study Group.
Nelson JD; Gordon JF
Am J Ophthalmol; 1992 Oct; 114(4):441-7. PubMed ID: 1415455
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of 0.05% micellar nano-particulate (MNP) cyclosporine ophthalmic emulsion in the treatment of moderate-to-severe keratoconjunctivitis sicca: a 12-week, multicenter, randomized, active-controlled trial.
Rao AT; Gupta A; Chauhan T; Basu S; Batra N; Sharma N; Sangwan VS; Gupta V; Mukherjee S
BMC Ophthalmol; 2023 Mar; 23(1):121. PubMed ID: 36973703
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial. The Cyclosporin A Phase 2 Study Group.
Stevenson D; Tauber J; Reis BL
Ophthalmology; 2000 May; 107(5):967-74. PubMed ID: 10811092
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of OTX-101, a Novel Nanomicellar Formulation of Cyclosporine A, for the Treatment of Keratoconjunctivitis Sicca: Pooled Analysis of a Phase 2b/3 and Phase 3 Study.
Sheppard J; Kannarr S; Luchs J; Malhotra R; Justice A; Ogundele A; Darby C; Bacharach J
Eye Contact Lens; 2020 Jan; 46 Suppl 1():S14-S19. PubMed ID: 31361655
[TBL] [Abstract][Full Text] [Related]
10. Topical cyclosporin treatment of keratoconjunctivitis sicca in secondary Sjögren's syndrome.
Gündüz K; Ozdemir O
Acta Ophthalmol (Copenh); 1994 Aug; 72(4):438-42. PubMed ID: 7825408
[TBL] [Abstract][Full Text] [Related]
11. [Topical cyclosporine A 0.05% in the treatment of keratoconjunctivitis sicca].
Schrell C; Cursiefen C; Kruse F; Jacobi C
Klin Monbl Augenheilkd; 2012 May; 229(5):548-53. PubMed ID: 22189827
[TBL] [Abstract][Full Text] [Related]
12. Treatment of keratoconjunctivitis sicca in dogs with cyclosporine ophthalmic ointment: a European clinical field trial.
Sansom J; Barnett KC; Neumann W; Schulte-Neumann A; Clerc B; Jegou JP; de Haas V; Weingarten A
Vet Rec; 1995 Nov; 137(20):504-7. PubMed ID: 8588275
[TBL] [Abstract][Full Text] [Related]
13. Spontaneous canine keratoconjunctivitis sicca. A useful model for human keratoconjunctivitis sicca: treatment with cyclosporine eye drops.
Kaswan RL; Salisbury MA; Ward DA
Arch Ophthalmol; 1989 Aug; 107(8):1210-6. PubMed ID: 2757551
[TBL] [Abstract][Full Text] [Related]
14. Clinical evaluation of 1% cyclosporine for topical treatment of keratoconjunctivitis sicca in dogs.
Olivero DK; Davidson MG; English RV; Nasisse MP; Jamieson VE; Gerig TM
J Am Vet Med Assoc; 1991 Oct; 199(8):1039-42. PubMed ID: 1748606
[TBL] [Abstract][Full Text] [Related]
15. Long-term Supplementation With n-6 and n-3 PUFAs Improves Moderate-to-Severe Keratoconjunctivitis Sicca: A Randomized Double-Blind Clinical Trial.
Sheppard JD; Singh R; McClellan AJ; Weikert MP; Scoper SV; Joly TJ; Whitley WO; Kakkar E; Pflugfelder SC
Cornea; 2013 Oct; 32(10):1297-304. PubMed ID: 23884332
[TBL] [Abstract][Full Text] [Related]
16. Sodium hyaluronate in the treatment of keratoconjunctivitis sicca. A double masked clinical trial.
Sand BB; Marner K; Norn MS
Acta Ophthalmol (Copenh); 1989 Apr; 67(2):181-3. PubMed ID: 2658462
[TBL] [Abstract][Full Text] [Related]
17. Comparison of 1% cyclosporine eye drops in olive oil and in linseed oil to treat experimentally-induced keratoconjunctivitis sicca in rabbits.
Parrilha LR; Nai GA; Giuffrida R; Barbero RC; Padovani LD; Pereira RH; Silva DA; Silva MC; Diniz MS; Andrade SF
Arq Bras Oftalmol; 2015; 78(5):295-9. PubMed ID: 26466228
[TBL] [Abstract][Full Text] [Related]
18. Topical administration of cyclosporine for treatment of keratoconjunctivitis sicca in dogs.
Morgan RV; Abrams KL
J Am Vet Med Assoc; 1991 Oct; 199(8):1043-6. PubMed ID: 1748607
[TBL] [Abstract][Full Text] [Related]
19. Effect of OTX-101, a Novel Nanomicellar Formulation of Cyclosporine A, on Corneal Staining in Patients With Keratoconjunctivitis Sicca: A Pooled Analysis of Phase 2b/3 and Phase 3 Studies.
Malhotra R; Devries DK; Luchs J; Kabat A; Schechter BA; Shen Lee B; Shettle L; Smyth-Medina R; Ogundele A; Darby C; Bacharach J; Karpecki P
Cornea; 2019 Oct; 38(10):1259-1265. PubMed ID: 31306284
[TBL] [Abstract][Full Text] [Related]
20. Estrogen therapy in keratoconjunctivitis sicca.
Akramian J; Wedrich A; Nepp J; Sator M
Adv Exp Med Biol; 1998; 438():1005-9. PubMed ID: 9635003
[No Abstract] [Full Text] [Related]
[Next] [New Search]
